naltrexone / Generic mfg. - LARVOL DELTA

Racial and ethnic disparities in medication for opioid use disorder treatment among medicaid enrollees. (PubMed, Drug Alcohol Depend) - "Results highlight the critical need to identify and address ongoing barriers to MOUD, particularly for minoritized groups, and for further research to understand and address state-level variation in these disparities."

Journal • Reimbursement • US reimbursement • Addiction (Opioid and Alcohol) • Substance Abuse

Sustained-Release Naltrexone for Treatment of Opioid Use Disorder. (PubMed, Am Fam Physician) - No abstract available

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

Quality Improvement Initiative to Increase Medication-Assisted Therapy for Alcohol Use Disorder in the Inpatient Setting (ACG 2026) - "There were no statistically significant differences between the pre-intervention (n = 21) and post-intervention (n = 22) groups with respect to age (51 vs 49, p = 0.74), 30-day readmission (19% vs 23%, p = 0.77); face-to-face physician-led alcohol cessation counselling (81% vs 86%, p = 0.70); naltrexone initiated inpatient (10% vs 27% p = 0.24); naltrexone prescribed on discharge increased 33% to 46% (absolute increase 13 percent, p = 0.42). Workflow documentation was charted in 4 of 22 patients. A structured, multidisciplinary MAT prescribing workflow is feasible within a teaching hospital inpatient setting."

Clinical • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology

Frontline Provider Attitudes, Practices, and Barriers to Alcohol Use Disorder Pharmacotherapy in Patients With Alcohol-Associated Liver Disease: A Multispecialty Survey (ACG 2026) - "While most recognized FDA-approved AUD medications (naltrexone 82.7%, acamprosate 84.5%), recognition of their utility in cirrhosis fell to 38.1% and 51.8% and 35.7% felt their risk outweighed the benefits in ALD cirrhosis... 179 providers responded across internal medicine (62.0%), emergency medicine (22.9%), family medicine (7.3%), psychiatry/addiction medicine (7.3%), and GI/hepatology (5.0%); 53.1% were trainees and 44.1% attendings, with 86.6% encountering ALD patients at least monthly. Only 36.3% felt comfortable prescribing AUD pharmacotherapy, and only 26.8% were regular prescribers. 66.1% incorrectly believed there is a safe level of alcohol use in liver disease."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Fibrosis • Hepatology • Immunology

Comparative Efficacy and Safety of IBAT Inhibitors, Bezafibrate, Rifampin, and Naltrexone for Cholestatic Pruritus in Primary Biliary Cholangitis: A Systematic Review and Network Meta-Analysis (ACG 2026) - "Our network meta-analysis included 14 randomized controlled trials comprising 1,142 patients with primary biliary cholangitisâassociated cholestatic pruritus. The cohort was predominantly female (94.2%), with a mean age of 52.8 years and severe baseline pruritus (mean WI-NRS 7.2±1.1). Treatment allocation included Linerixibat (n=238), Maralixibat (n=96), Odevixibat (n=82), Bezafibrate (n=184), Rifampin (n=112), Naltrexone (n=98), and placebo (n=332)."

Retrospective data • Review • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Burden of Alcoholic Liver Disease and Underutilization of FDA-Approved Medication for Alcohol Use Disorder: A Real-World Analysis (ACG 2026) - "Among patients with ALD, we assessed the incidence and prevalence of patient treated with MAUD, including naltrexone, acamprosate, and disulfiram...Off-label agents such as baclofen (7.2%) and topiramate (3.2%) were prescribed at rates exceeding disulfiram (1.2%)... We identified 2.639.758 patients with AUD. ALD incidence rose from 779 to 2,911 per 100,000 in females and 1,320 to 3,702 in males, while prevalence reached 7,484 in females and 9,288 in males by 2025. MAUD incidence among ALD patients was higher in females than males."

Clinical • Real-world • Real-world evidence • Addiction (Opioid and Alcohol) • Hepatology • Substance Abuse

Discharge AUD Pharmacotherapy Utilization and Readmission Outcomes at a VA Medical Center: A Quality Improvement Analysis (ACG 2026) - "Thirty-day readmission rates were 14.9% with naltrexone, 13.6% with acamprosate, and 20% without pharmacotherapy. Neither naltrexone (OR 0.80, p=0.41) nor acamprosate (OR 0.81, p=0.65) was associated with reduced 30-day readmissions. Prior alcohol-related admission was the strongest predictor (OR 2.78, p< 0.05)."

Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology

A Treatment Gap With Consequences: Underutilization of Medications for Opioid Use Disorder and Associated Mortality in Chronic Gastrointestinal Disease (ACG 2026) - "The primary outcome was initiation of MOUD (buprenorphine, methadone, or naltrexone) within 90 days of OUD diagnosis. After matching, 11,522 pairs were analyzed. Patients with GI-OUD were less likely to initiate MOUD within 90 days than matched patients with OUD alone (8.6% vs 9.8%; RR 0.88, 95% CI 0.81â0.95; p=0.002). Among GI-OUD patients, MOUD receipt was associated with lower all-cause mortality (2.9% vs 4.1%; RR 0.71, 95% CI 0.53â0.95) and reduced mortality risk (HR 0.66, 95% CI 0.49â0.89; p=0.019)."

Addiction (Opioid and Alcohol) • CNS Disorders • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Inflammatory Bowel Disease • Mental Retardation • Pancreatitis • Substance Abuse

Semaglutide Outperforms Naltrexone in Alcoholic Cirrhosis Outcomes: A Large-Scale TriNetX Retrospective Cohort Analysis (ACG 2026) - "Initially Naltrexone cohort had 3,854 patients and Semaglutide cohort 1,220. After PSM, 874 patients were included in each cohort. Semaglutide was associated with lower mortality (9.6% vs 21.0%; HR 2.04, p< 0.001), hospitalization (24.9% vs 49.0%; HR 2.37, p< 0.001), and ED visits (23.3% vs 48.7%; HR 2.62, p< 0.001)."

Retrospective data • Alpha-1 Antitrypsin Deficiency • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Movement Disorders • Nephrology • Obesity • Primary Biliary Cholangitis • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor • RAS

Comparative Efficacy and Tolerability of Pharmacological Agents for Cholestatic Pruritus in Primary Biliary Cholangitis: A Systematic Review and Network Meta-Analysis (ACG 2026) - "(c) Any adverse events: rifampin, sertraline, naltrexone, and linerixibat carried significantly higher adverse event rates versus placebo; nalfurafine 5 mg was the safest agent (P-score 0.82). Fourteen RCTs across 9 active treatment nodes were included. On continuous pruritus reduction, rifampin ranked first (SMD -4.21 [95% CI -7.12, -1.29]; P-score 0.90), followed by linerixibat (SMD -2.68 [-4.55, -0.80]; P-score 0.69) and naltrexone (SMD -2.62 [-4.73, -0.51]; P-score 0.68). For responder rate, rifampin led (RR 2.80 [1.29-6.05]), while linerixibat combined a significant responder rate (RR 1.69 [1.20-2.38]) with the highest P-score among well-powered trials (0.53)."

Retrospective data • Review • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Intermediate-Dose Naltrexone for Refractory Hailey–Hailey Disease in an Elderly Patient with Multiple Comorbidities: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Genetic Disorders

Novel pharmacotherapies for opioid use disorder and opioid withdrawal. (PubMed, Front Psychiatry) - "Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone...We conducted a narrative review of emerging pharmacologic approaches for OUD and opioid withdrawal syndrome, focusing on ketamine and NMDA receptor antagonists, cannabinoids, psychedelics, and incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists...Cannabidiol may reduce cue-induced craving and anxiety, whereas dronabinol may modestly suppress opioid withdrawal symptoms...Future studies should prioritize rigorous blinding assessment, active comparators, objective endpoints, standardized cue-reactivity measures, diverse samples, and careful safety monitoring. Regulatory policies should facilitate the development and implementation of future research in novel therapies for OUD."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Mood Disorders • Psychiatry • Substance Abuse

Perceptions of Technology and Digital Health Tools Among Recently Incarcerated Adults With Opioid Use Disorder: Semistructured Interview Study. (PubMed, J Med Internet Res) - "Participants were recruited from a randomized clinical trial (EXIT-CJS) comparing the effectiveness of extended-release buprenorphine, naltrexone, and enhanced treatment as usual on treatment retention...Accessing digital health was acknowledged as contingent on access to internet-capable devices, affordable connectivity, and digital literacy. The findings suggest that maximizing digital health's impact in reentry will require a multipronged approach: investing in infrastructure to close the digital divide, addressing upstream structural barriers to accessing care, and partnering with impacted persons to co-design hybrid care models that enhance the feasibility of engaging in care during reentry while enhancing therapeutic human connection and respecting patient preferences."

Clinical • Interview • Journal • Addiction (Opioid and Alcohol) • Substance Abuse

SOGC Clinical Practice Guideline No. 471: Alcohol and Pregnancy. (PubMed, J Obstet Gynaecol Can) - "RECOMMENDATIONS: (Recommendations IN BOLD are new to this guideline update; an overview of the updated supporting literature for all recommendations is provided in Appendix B)."

Clinical guideline • Journal • Addiction (Opioid and Alcohol) • Obstetrics

Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era. (PubMed, Drug Alcohol Depend Rep) - "This narrative review reconstructs the U.S. history of treating co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) from the rise of methadone maintenance in the 1960s through contemporary interest in immunometabolic mechanisms and repurposed therapies...Emerging GLP-1-based therapies may offer a distinctive cross-disorder adjunct, but their value for OUD/AUD remains unproven. Population benefit will require rigorous trials and delivery reforms that expand equitable access to integrated care."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse

Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ-Opioid Receptor via an Endoplasmic Reticulum Exit Site-Dependent Pathway. (PubMed, Pharmacol Res Perspect) - "In contrast, buprenorphine, methadone, and two allosteric modulators have no substantial effect on ERES levels. We also find that antagonist-induced pharmacological chaperoning depends on retrotransport from the Golgi as brefeldin A (BFA) treatment prevented pharmacological chaperoning. These data reveal new understandings of how opioid ligands change MOR trafficking from the ER and can help us better understand the pathophysiology of opioid use disorder."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse • ER

ACUTE EOSINOPHILIC PNEUMONIA DUE TO INJECTABLE NALTREXONE: A RARE PRESENTATION OF SEVERE HYPOXEMIC RESPIRATORY FAILURE (CHEST 2026) - No abstract available

Infectious Disease • Pneumonia • Respiratory Diseases

SUPPLEMENT WITH ICU CONSEQUENCES: NALTREXONE-PRECIPITATED KRATOM WITHDRAWAL (CHEST 2026) - No abstract available

Critical care

NALTREXONE-INDUCED PRECIPITATED OPIOID WITHDRAWAL COMPLICATED BY TAKOTSUBO CARDIOMYOPATHY AND CARDIOGENIC SHOCK (CHEST 2026) - No abstract available

Cardiomyopathy • Cardiovascular

An Analysis of Treatment Preferences of Patients With Opioid Use Disorders: Findings From A Tertiary Drug Dependence Treatment Center in India. (PubMed, Addict Health) - "The options included naltrexone (oral, depot, and implant), buprenorphine (sublingual and injection), methadone, tramadol, counselling/psychotherapy, long-term residential treatment, Narcotics Anonymous meetings, and no treatment. A wider availability of medications for opioid agonist maintenance treatment could improve treatment-seeking rates. Further research on treatment preference could include diverse patient groups, caregivers, and treatment providers."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

Dental caries associated with medications for opioid use disorder: drug effects, formulation factors, or both? (PubMed, Int J Pharm) - "Medications for opioid use disorder (MOUD) have reduced fentanyl-related mortality by approximately 20% over the past five years...Two key questions remain unresolved: (1) Why are buprenorphine (BUP) and methadone (MTD) associated with dental complications, whereas naltrexone (NLX) carries a substantially lower risk?...Importantly, comprehensive oral health care will improve patients' life quality, leading to better adherence, suggesting that understanding and preventing this adverse effect may improve adherence and long-term clinical outcomes. Among available MOUDs, transmucosal BUP provides a clinically relevant model for addressing current mechanistic gaps and developing preventive, formulation-based, and administration route-informed interventions."

Journal • Review • Addiction (Opioid and Alcohol) • Dental Disorders • Substance Abuse

A scoping review of naltrexone treatment for opioid use disorder: Clinical hurdles and successes. (PubMed, Prev Med) - "Naltrexone is the least utilized medication for OUD because of induction-related clinical hurdles despite its comparable post-stabilization effectiveness with other medications for OUD. Further research is warranted on how to expand its clinical use."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

EPF-02 - Real-World Opioid Use Disorder Pharmacotherapy: Where Innovation Meets Regulation (PAINWeek 2026) - "This session moves beyond naloxone and buprenorphine to examine all four pillars of opioid use disorder pharmacotherapy — naloxone, methadone, buprenorphine, and naltrexone — across the continuum from harm reduction to treatment. Manage precipitated withdrawal across its three mechanisms: naloxone over-reversal, premature buprenorphine induction, and naltrexone initiation without washout. Formulate strategies to overcome structural and pharmacy-level barriers and improve equitable access and adherence to OUD medications."

Clinical • Real-world • Real-world evidence • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences (clinicaltrials.gov) - P1 | N=217 | Completed | Sponsor: San Diego State University | Recruiting ➔ Completed | Trial completion date: Jul 2027 ➔ Mar 2026 | Trial primary completion date: Apr 2027 ➔ Mar 2026

Trial completion • Trial completion date • Trial primary completion date

Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies. (PubMed, Medicina (Kaunas)) - "Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily indirectly through weight reduction and metabolic improvement...However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required."

Clinical • Journal • Review • Diabetes • Genetic Disorders • Gestational Diabetes • Gynecology • Infertility • Inflammation • Metabolic Disorders • Obesity • Polyendocrine Metabolic Ovarian Syndrome • Sexual Disorders • Women's Health • LEP